Ongoing clinical Trial - TTX-CINP-202
TTX-CINP-202 is a randomized, phase 2 clinical trial evaluating the safety and effectiveness of TTX vs placebo in people with established neuropathy due to their chemotherapy. Participants are expected to complete laboratory exams (blood work) and questionnaires to evaluate eligibility, safety, and quality of life. If eligible, participants will receive 8 doses of TTX or placebo over 4 days and be followed for 90 days for safety and effectiveness. TTX-CINP-202 is enrolling up to 222 people who have Chemotherapy Induced Neuropathic Pain (CINP) due to a Platinum or Taxane based chemotherapy regimen. Participants may be assigned to either an active treatment arm or the control arm of the trial.
TTX-CINP-202 is enrolling at sites based in the United States, Canada, South Korea, and Taiwan. A current list of trial sites can be found at Clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT05359133?term=ttx&draw=2&rank=6)
Who can participate?
This trial is open to adults aged 21 and older who have been diagnosed with moderate-to-severe CINP due to Platinum or Taxane chemotherapy, and are not receiving any opioid or cytotoxic chemotherapy (hormone therapy is allow). Participants must not have clinical evidence of actively progressive disease. Specific eligibility criteria and exclusions can be found at Clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT05359133?term=ttx&draw=2&rank=6)
To request more information about participating in our clinical trials, please contact:
WEX is in process of launching its pivotal phase III trial for Halneuron® to treat Chemotherapy-Induced Neuropathic Pain (CINP) in the United States and Canada.
Please revisit this page for patient, physician and clinical trial site information upon commencement of the trial.